I euglykæmiske clamp- forsøg på raske forsøgspersoner og type 1- diabetikere var tidspunktet for virkningens indtræden af subkutant insulin glargin langsommere end ved humant NPH insulin, og virkningsprofilen var jævn og uden koncentrationstoppe, og virkningens varighed var forlænget.
In euglycaemic clamp studies in healthy subjects or in patients with type 1 diabetes, the onset of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect profile was smooth and peakless, and the duration of its effect was prolonged.